Frankfurt, Germany – January 30, 2026 — Merz Therapeutics has announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. The leadership move marks a strategic step as the company strengthens its European operations and advances its long-term growth ambitions across key pharmaceutical markets. Staner will report directly to CEO Stefan König and join the Therapeutics Executive Team, underscoring the importance of Europe in Merz Therapeutics’ global strategy.
Science Significance
While this announcement is a leadership update, its scientific relevance lies in execution. Merz Therapeutics is deeply focused on specialty neurology, movement disorders, neurodegenerative diseases, and liver disease, areas that require sustained clinical development, real-world evidence generation, and close collaboration with healthcare systems. Strong regional leadership is critical to translating scientific innovation into clinical adoption, ensuring that approved and pipeline therapies are effectively integrated into care pathways across diverse European healthcare environments. Staner’s experience in guiding market launches and cross-functional teams directly supports the scientific lifecycle from late-stage development to post-marketing optimization.
Regulatory Significance
Europe represents one of the most complex regulatory landscapes for pharmaceuticals, spanning centralized EMA procedures and country-specific reimbursement and access frameworks. As President, Region Europe, Staner will play a pivotal role in aligning commercial strategy with regulatory requirements, including post-approval commitments, pharmacovigilance, and market access negotiations. His leadership is expected to strengthen coordination between regulatory, medical affairs, and commercial teams, ensuring timely patient access while maintaining strict compliance with European regulatory standards.
Business Significance
Advertisement
From a business perspective, the appointment reflects Merz Therapeutics’ commitment to scalable and sustainable growth in Europe. Staner brings a proven track record of regional P&L leadership, successful product launches, and organizational transformation within the biopharmaceutical sector. His mandate includes driving commercial execution, optimizing the regional portfolio, and deepening partnerships with healthcare stakeholders. Following a planned leadership transition after the departure of Marcus Gollub, this move provides continuity while positioning the company to capitalize on growth opportunities across established and emerging European markets.
Patients’ Significance
For patients, leadership decisions matter because they directly influence access, availability, and continuity of innovative therapies. Merz Therapeutics’ focus on conditions that significantly impact quality of life means that effective regional leadership can accelerate access to treatments for patients with high unmet needs. By strengthening European operations, the company aims to ensure that therapies reach patients faster, are supported by robust medical education, and are embedded into clinical practice with a strong patient-centric approach.
Policy Significance
Healthcare policy across Europe is evolving rapidly, with increasing emphasis on value-based care, cost containment, and equitable access. As President, Region Europe, Staner will need to navigate these dynamics, working closely with policymakers, payers, and healthcare providers. His role will be essential in aligning Merz Therapeutics’ portfolio with national health priorities, supporting policies that encourage innovation while demonstrating real-world value and outcomes.
The appointment of Dan Staner as President, Region Europe signals a strategic inflection point for Merz Therapeutics as it reinforces its leadership structure to support growth, regulatory excellence, and patient access across Europe. With deep experience in biopharmaceutical leadership and a mandate to align regional execution with global strategy, Staner is positioned to help the company advance specialty therapies, strengthen market presence, and deliver long-term value for patients and healthcare systems alike. As Merz Therapeutics continues to expand its impact in neurology and other specialty areas, this leadership transition underscores the company’s focus on disciplined growth and patient-centered innovation.
Source: Merz Therapeutics press release
